Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany

This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Florian, Arefian, Habibollah, Hartmann, Michael, Runnebaum, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714746/
https://www.ncbi.nlm.nih.gov/pubmed/36454738
http://dx.doi.org/10.1371/journal.pone.0278460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714746/
https://www.ncbi.nlm.nih.gov/pubmed/36454738
http://dx.doi.org/10.1371/journal.pone.0278460

Ejemplares similares